The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Open accessAbstract
BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Similarly, in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) and Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trials, treatment with CETP inhibitors more than doubled HDL-C levels, but did not appear to reduce the risk of ASCVD events beyond”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Evacetrapib, which raises HDL-C levels by 130% and lowers LDL-C by 37%, was studied in the ACCELERATE trial [63], which was terminated due to futility.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“The CETP inhibitors dalcetrapib (in > 30 000 patients with recent ACS [65]) and evacetrapib (in > 12 000 high-risk patients [63]) were investigated in 2012 and 2017, respectively. Neither clinical study was able to show any clinical benefit associated with CETP inhibitors [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Colocalization, which is a statistical approach that quantifies the extent to which two traits share the same underlying causal variant, and thus can be used to infer vertical pleiotropy 83-85 , can be used to test for such bias 86 , but can suffer from issues of lack of power and/or availability of suitable data from relevant tissues.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
In the citing paper
“Confounding by linkage disequilibrium can be assessed through colocalization 84”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Flagged first, then by citations
Research works printed but not linked: 1
- Krishna R, Clin Pharmacol Ther
Cited by
Sorted by citations
Items 401–500 of 1,001
Emerging drugs for the treatment of hypercholesterolemia
Bove, M., Cicero, A. F. G., & Borghi, C. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1591372 · Cited by 21
Zhang, X., Qin, Y., Wan, X., Liu, H., Iv, C., Ruan, W., Lü, L., He, L., & Guo, X. (2020) · BioMed Research International · doi:10.1155/2020/5036572 · Cited by 21
Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels
Eraikhuemen, N. E., Lazaridis, D., & Dutton, M. T. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00437-7 · Cited by 21
Genetic Variation in Sodium‐glucose Cotransporter 2 and Heart Failure
Katzmann, J. L., Mason, A. M., März, W., Kleber, M. E., Niessner, A., Blüher, M., Speer, T., & Laufs, U. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2153 · Cited by 21
Umbrella Review on Non-Statin Lipid-Lowering Therapy
Beshir, S. A., Hussain, N., Elnour, A. A., & Said, A. S. A. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211002943 · Cited by 21
Adam, S., Ho, J. H., Liu, Y., Siahmansur, T. J., Siddals, K. W., Iqbal, Z., Azmi, S., Senapati, S., New, J. P., Jeziorska, M., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac244 · Cited by 22
Effects of blood lipids and lipid‐modifying drugs on intracranial aneurysms
Zhang, B., Dong, S., Miao, Y., Song, G., Yuan, F., Liu, L., Xia, S., Qin, Y., Huo, X., Wu, Z., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15471 · Cited by 21
Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor
Koschinsky, M. L., Stroes, E. S. G., & Kronenberg, F. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106843 · Cited by 22
Unexplained reciprocal regulation of diabetes and lipoproteins
Higuchi, S., Izquierdo, M. C., & Haeusler, R. A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000521 · Cited by 20
Towards more specific treatment for diabetic dyslipidemia
Rodriguez, V., Newman, J. D., & Schwartzbard, A. Z. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000528 · Cited by 21
The mystery of evacetrapib - why are CETP inhibitors failing?
Nicholls, S. J., & Bubb, K. J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1745633 · Cited by 21
Gu, Z., Liu, T., Rao, W., Li, D., Zhang, Q., Dai, J., Huang, L., Wang, J., & Hou, X. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202412335 · Cited by 20
High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?
Liu, K., Cooper, M. E., Chai, Z., & Liu, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041683 · Cited by 20
LDL cholesterol: How low to go?
Packard, C. J. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.12.011 · Cited by 20
Sorokin, A. V., Patel, N. H., Abdelrahman, K. M., Ling, C., Reimund, M., Graziano, G., Sampson, M. L., Playford, M. P., Dey, A. K., Reddy, A. S., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159577 · Cited by 20
Bonaca, M. P., Morrow, D. A., Bergmark, B. A., Berg, D. D., Lima, J. A. C., Hoffmann, U., Kato, Y., Lu, M. T., Kuder, J., Murphy, S. A., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059325 · Cited by 20
Liu, J., Wang, B., Li, Y., Yan, X., Li, J., & Li, J. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.12.003 · Cited by 20
Paraoxonase 1: evolution of the enzyme and of its role in protecting against atherosclerosis
Durrington, P. N., & Soran, H. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000936 · Cited by 20
Lipoprotection in cardiovascular diseases
Benkhoff, M., & Polzin, A. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108747 · Cited by 20
Generoso, G., Benseñor, I. M., Santos, R. D., Santos, I. S., Goulart, A. C., Jones, S. R., Kulkarni, K. R., Blaha, M. J., Toth, P. P., Lotufo, P. A., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.05.003 · Cited by 20
Apolipoprotein CIII and diabetes. Is there a link?
Christopoulou, E. C., Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3118 · Cited by 21
Hou, L., Tang, S., Wu, B. J., Ong, K. L., Westerterp, M., Barter, P. J., Cochran, B. J., Tabet, F., & Rye, K. (2019) · The FASEB Journal · doi:10.1096/fj.201802512rr · Cited by 20
Warden, B. A., Minnier, J., Watts, G. F., Fazio, S., & Shapiro, M. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.008 · Cited by 20
Langlois, M. R., & Nordestgaard, B. G. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1036-1 · Cited by 19
Schleyer, T., Hui, S., Wang, J., Zhang, Z., Knapp, K., Baker, J., Chase, M., Boggs, R., & Simpson, R. J. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.5.544 · Cited by 19
Abidor, E., Achkar, M. A., Saidi, I. A., Lather, T., Jdaidani, J., Agarwal, A., & El‐Sayegh, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020643 · Cited by 23
Bias and Loss to Follow‐Up in Cardiovascular Randomized Trials: A Systematic Review
Fong, L. C. W., Ford, T. J., da Costa, B. R., Jüni, P., & Berry, C. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015361 · Cited by 19
Sacks, F. M., Furtado, J. D., & Jensen, M. K. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159182 · Cited by 19
New Insights into Pathophysiology and New Risk Factors for ACS
Nardin, M., Verdoia, M., Laera, N., Cao, D., & Luca, G. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082883 · Cited by 21
Recent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 19
Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155082 · Cited by 20
Yu, C., Bakshi, A., Watts, G. F., Renton, A. E., Fulton‐Howard, B., Goate, A., Natarajan, P., Chasman, D. I., Robman, L. D., Woods, R. L., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031459 · Cited by 20
New approaches to address dyslipidemia
Parhofer, K. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000456 · Cited by 19
Direct Estimation of HDL-Mediated Cholesterol Efflux Capacity from Serum
Kuusisto, S. M., Holmes, M. V., Ohukainen, P., Kangas, A. J., Karsikas, M., Tiainen, M., Perola, M., Salomaa, V. V., Kettunen, J., & Ala‐Korpela, M. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.299222 · Cited by 20
Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations
Heine, G. H., Eller, K., Stadler, J. T., Rogacev, K. S., & Marsche, G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107459 · Cited by 19
Arsenault, B. J., Perrot, N., & Puri, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1110 · Cited by 21
Trompet, S., Packard, C. J., & Jukema, J. W. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000476 · Cited by 19
Commentary on Fit-For-Purpose Models for Regulatory Applications
Wang, Y., & Huang, S. M. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.09.009 · Cited by 19
Factors Influencing Stent Failure in Chronic Total Occlusion Coronary Intervention
Mahadevan, K., Cosgrove, C., & Strange, J. (2021) · Interventional Cardiology Reviews Research Resources · doi:10.15420/icr.2021.03 · Cited by 18
Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
Rikhi, R. R., & Shapiro, M. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154611 · Cited by 19
New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease
Nestel, P. J., Loh, W. J., Ward, N. C., & Watts, G. F. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac541 · Cited by 19
Zvintzou, E., Xepapadaki, E., Skroubis, G., Mparnia, V., Giannatou, K., Benabdellah, K., & Kypreos, K. E. (2023) · Pharmaceuticals · doi:10.3390/ph16060855 · Cited by 22
Păunică, I., Mihai, A. D., Ștefan, S., Stoian, A. P., & Serafinceanu, C. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108634 · Cited by 18
Wilson, D. P., Friedman, M., Marulkar, S., Hamby, T., & Bruckert, É. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.020 · Cited by 18
Chaiyasothi, T., Nathisuwan, S., Dilokthornsakul, P., Vathesatogkit, P., Thakkinstian, A., Reid, C. M., Wongcharoen, W., & Chaiyakunapruk, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00547 · Cited by 19
Váchal, P., Duffy, J. L., Campeau, L., Amin, R. P., Mitra, K., Murphy, B. A., Shao, P. P., Sinclair, P. J., Ye, F., Katipally, R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00959 · Cited by 18
Chapman, M. J., Orsoni, A., Robillard, P., Thérond, P., & Giral, P. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.001 · Cited by 18
Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1114 · Cited by 19
Environmental Factors Modifying HDL Functionality
Kostara, C. E., Kosmas, C. E., Sourlas, A., & Guzman, E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210714155422 · Cited by 17
Lorkowski, S. W., & Smith, J. D. (2022) · Biomedicines · doi:10.3390/biomedicines10010128 · Cited by 18
High density lipoprotein: When to rethink too much of a good thing
Dastmalchi, L. N., German, C. A., & Taub, P. R. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100511 · Cited by 18
Ferrières, J., Lautsch, D., Ambegaonkar, B. M., Ferrari, G. M. D., Vyas, A., Baxter, C. A., Bash, L. D., Velkovski-Rouyer, M., Horack, M., Almahmeed, W. A., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.06.008 · Cited by 18
Recent Advances in the Development of Vaccines for Diabetes, Hypertension, and Atherosclerosis
Lu, K., Su, B., & Meng, X. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1638462 · Cited by 18
CETP inhibition, statins and diabetes
Barter, P. J., Cochran, B. J., & Rye, K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.033 · Cited by 17
Singh, R. K., Lund, F. W., Haka, A. S., & Maxfield, F. R. (2019) · Journal of Cell Science · doi:10.1242/jcs.237271 · Cited by 17
Symptomatic and asymptomatic intracranial atherosclerotic stenosis: 3 years’ prospective study
Fischer, U., Hsieh, K., Kellner‐Weldon, F., Galimanis, A., Yan, X., Kaesmacher, J., El‐Koussy, M., Jung, S. C., Arnold, M., Michel, P., et al. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09750-2 · Cited by 17
Trinder, M., & Brunham, L. R. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000737 · Cited by 17
Davenport, E. D., Gray, G. W., Rienks, R., Bron, D., Syburra, T., D’Arcy, J. L., Guettler, N. J., Manen, O., & Nicol, E. D. (2018) · Heart · doi:10.1136/heartjnl-2018-313054 · Cited by 17
Zhang, Y., Li, F., Liu, L., An, Z., Luo, H., Zhang, H., Ma, R., Zhang, R., Dai, Q., Zhang, M., et al. (2025) · Advanced Science · doi:10.1002/advs.202504990 · Cited by 19
Using Human Genetics to Drive Drug Discovery: A Perspective
Fox, C. S. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.12.045 · Cited by 16
A review of therapeutic failures in late-stage clinical trials
Jain, R., Subramanian, J., & Rathore, A. S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2161366 · Cited by 18
Clinical Pharmacokinetics and Pharmacodynamics of CSL112
Ortega‐Paz, L., Giordano, S. A., Capodanno, D., Mehran, R., Gibson, C. M., & Angiolillo, D. J. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01224-8 · Cited by 16
HDL as a Treatment Target: Should We Abandon This Idea?
Bègue, F., Apalama, M. L., Lambert, G. C., & Meilhac, O. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01176-1 · Cited by 16
Cicero, A. F. G., Bove, M., & Borghi, C. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1416094 · Cited by 17
Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
Black, D. M., Bentley, D. J., Chapel, S. H., Lee, J.-T., Briggs, E., & Heinonen, T. M. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0656-3 · Cited by 16
Gutiérrez‐Vidal, R., Delgado‐Coello, B., Méndez-Acevedo, K. M., Calixto-Tlacomulco, S., Damián-Zamacona, S., & Mas‐Oliva, J. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.01.007 · Cited by 16
Oshita, T., Toh, R., Nagano, Y., Kuroda, K., Nagasawa, Y., Harada, A., Murakami, K., Kiriyama, M., Yoshikawa, K., Miwa, K., et al. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.01.001 · Cited by 16
Chen, C., Liu, X., Liu, L., Lo, K. K.-H., Yu, Y., Huang, J., Huang, Y., & Chen, J. (2020) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s272624 · Cited by 15
Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist’s Perspective
Jurcău, A., & Simion, A. (2021) · Medicina · doi:10.3390/medicina57060616 · Cited by 16
Holmes, M. V., & Smith, G. D. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.10.006 · Cited by 16
Patel, P. N., & Giugliano, R. P. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.39 · Cited by 19
Aortic valvular stenosis: Novel therapeutic strategies
Natorska, J., Kopytek, M., & Undas, A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13527 · Cited by 15
Bilgic, S., Pencina, K. M., Pencina, M. J., Cole, J., Dufresne, L., Thanassoulis, G., & Sniderman, A. D. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321165 · Cited by 15
Papafaklis, M. I., Koros, R., Tsigkas, G., Καρανάσος, Α., Μούλιας, Α., & Davlouros, P. A. (2024) · Biomedicines · doi:10.3390/biomedicines12112435 · Cited by 17
An updated review of lipid‐modifying therapy
Simons, L. A. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50142 · Cited by 18
Masana, L., & Plana, N. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.04.005 · Cited by 15
Update of therapeutic planning tables oriented towards obtaining therapeutic objectives
Masana, L., & Plana, N. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.10.001 · Cited by 15
Raposo, H. F., Forsythe, P., Chausse, B., Castelli, J. Z., Moraes‐Vieira, P. M., Nunes, V. S., & Oliveira, H. C. F. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154429 · Cited by 15
Cholesterol metabolism and tumor
Meng, Y., Wang, Q., & Zhimin, L. Y. U. (2021) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2021-0033 · Cited by 15
Aguilar-Ramirez, D. J., Alegre-Díaz, J., Herrington, W. G., Staplin, N., Ramírez-Reyes, R., Gnatiuc, L., Hill, M., Romer, F., Torres, J., Trichia, E., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab497 · Cited by 15
Casteleijn, M. G., Parkkila, P., Viitala, T., & Koivuniemi, A. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m082685 · Cited by 15
Davenport, E. D., Syburra, T., Gray, G. W., Rienks, R., Bron, D., Manen, O., D’Arcy, J. L., Guettler, N. J., & Nicol, E. D. (2018) · Heart · doi:10.1136/heartjnl-2018-313055 · Cited by 15
HDL-Targeted Therapies During Myocardial Infarction
Sposito, A. C., do Carmo, H. R. P., Barreto, J., Sun, L., de Carvalho, L. S. F., Feinstein, S. B., Zanotti, I., Kontush, A., & Remaley, A. T. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06865-1 · Cited by 15
Evacetrapib reduces preβ-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes
Chen, Y., Dong, J., Zhang, X., Chen, X., Wang, L., Chen, H., Ge, J., & Jiang, X. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.04.211 · Cited by 16
Lipid trafficking in cardiovascular disease
Sposito, A. C., Zimetti, F., Barreto, J., & Zanotti, I. (2019) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.04.002 · Cited by 16
Is hypertriglyceridemia atherogenic?
Huet, F., Roubille, C., & Roubille, F. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000622 · Cited by 15
Baum, S. J., & Scholz, K. P. (2019) · Clinical Cardiology · doi:10.1002/clc.23220 · Cited by 15
Pharmacokinetics of current and emerging treatments for hypercholesterolemia
Tomlinson, B., Chan, P., Zhang, Y., Liu, Z., & Lam, C. W. K. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1749261 · Cited by 16
Yamashita, S., Okazaki, M., Okada, T., Masuda, D., Yokote, K., Arai, H., Araki, E., & Ishibashi, S. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60764 · Cited by 14
Davidson, M. H., Hsieh, A., & Kastelein, J. J. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000955 · Cited by 15
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
Ahmad, M. I., & Shapiro, M. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00913-8 · Cited by 14
Schäfer, A., Akin, M., Diekmann, J., & König, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061509 · Cited by 16
Impact of Lipoprotein (a) on Long-Term Outcomes in Patients With Acute Myocardial Infarction
Dai, K., Shiode, N., Yoshii, K., Kimura, Y., Matsuo, K., Jyuri, Y., Tomomori, S., Higaki, T., Oi, K., Kawase, T., et al. (2023) · Circulation Journal · doi:10.1253/circj.cj-23-0221 · Cited by 14
Mormone, A., Tortorella, G., Esposito, F., Caturano, A., Marrone, A., Cozzolino, D., Galiero, R., Marfella, R., Sasso, F. C., & Rinaldi, L. (2024) · Biomedicines · doi:10.3390/biomedicines12020432 · Cited by 17
Wang, Y., Li, H., Zhang, Z., Wu, F., Liu, J., Zhu, Z., & Xiang, H. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02313-8 · Cited by 16
LP(a): The new marker of high cardiovascular risk
Averna, M. R., & Cefalu, A. B. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.103845 · Cited by 14
KEECH, A. C., & Jenkins, A. J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000465 · Cited by 14
Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?
Ellis, K. L., & Watts, G. F. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.010 · Cited by 16
Cholesteryl ester transfer protein inhibitors in precision medicine
Su, X., Li, G., Deng, Y., & Chang, D. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.09.012 · Cited by 14
Zhou, R., Stouffer, G. A., & Smith, S. C. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211023632 · Cited by 15
Metadata
- Authors
- The HPS3/TIMI55–REVEAL Collaborative Group
- Affiliations
- University of Oxford (GB)
- Corresponding author
- The HPS3/TIMI55–REVEAL Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-09-28
- Volume
- 377
- Issue
- 13
- Pages
- 1217-1227
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2762777606
- Cited by
- 1,047
- References
- 28
- Citations by year
- 2026: 72 · 2025: 78 · 2024: 99 · 2023: 92 · 2022: 93 · 2021: 118 · 2020: 107 · 2019: 134 · 2018: 195 · 2017: 54
- FWCI
- 137.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10139, NF-SI-0508-10299, RC-PG-0407-10054)
- British Heart Foundation (FS/14/55/30806)
- Versus Arthritis (20639, 18475)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- anacetrapib, cholesteryl ester transfer protein inhibition, atherosclerosis, coronary events, myocardial infarction, coronary revascularization, coronary death, HDL cholesterol, non-HDL cholesterol, LDL cholesterol, atorvastatin, statin therapy, cardiovascular risk reduction, serious adverse events, cancer risk, drug safety, subgroup analysis
- MeSH terms
- Aged, Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Oxazolidinones, Atherosclerosis, Kaplan-Meier Estimate, Cholesterol Ester Transfer Proteins, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
